C Wrigglesworth requested Dr Walford's views on whether any action was required in relation to the stocks of pre-March 1983 material and suggested there was a conflict between the result of the FDA meeting and the 13 July CSM(B) recommendation.
Chronology Information
Date:
Chapter/issue
Blood Products and Addressing Risk: Regulation of Commercial Factor Concentrates
Key Person(s)
Dr Diana Walford